Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.

NCT Number	NCT03017573
Lead Sponsor	Institut Curie
Conditions	Ovarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical Cancer, Sarcoma, Vulva Cancer
Enrollment	1,050 participants
Start Date	2017-01-06
Primary Completion	2029-08-06 (estimated)
Study Completion	2032-01-06 (estimated)
Updated on ClinicalTrials.gov	2026-02-03